Esperion unveils positive human trial results for new cholesterol-lowering drug
Esperion said that bempedoic acid is under development as a complementary, cost-effective, once-daily and oral therapy to treat patients with elevated LDL-C. The company has submitted new drug
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.